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BRIEF INTRODUCTION

DIAGNOSTIC IMAGING

MANAGEMENT

Neurofibromatosis type 1 (NF-1) is a multisystem neurocutaneous disorder resulting from mutations in
the NF-1 gene on chromosome 17 (q11.2). Mutations in NF-1 result in deficient activity of the tumor
suppressor protein neurofibromin, allowing for uncontrolled constitutive activity of the proliferative Raspathway in several neural cell types, including neurons, oligodendrocytes, astrocytes and Schwann
cells.1 Half of NF-1 cases are inherited in autosomal dominant fashion, while half develop sporadically.
The syndrome has 100% penetrance but highly variable expressivity. The prevalence of this syndrome is
1/3,000, making it common enough to warrant YOU, the physician, taking a moment to learn how to
recognize and manage it.

Most diagnoses of NF-1 can be made by physical exam and history alone. However, in cases where
history and physical raise significant clinical suspicion but are not diagnostic, opthalmologic evaluation
and diagnostic imaging are indicated. More importantly, many of the major causes of morbidity and
mortality in NF-1 lurk internally, making diagnostic imaging universally indicated and crucially important
during the evaluation of newly-diagnosed neurofibromatosis patients.

The diversity of medical professionals involved in the management of patients with NF-1
mirrors the diversity of its pathological manifestations. Caring for the neurofibromatosis
patient is truly a multidisciplinary endeavor and commonly includes the participation of at
least the following clinicians: geneticist (diagnosis and coordination of care), PCP
(coordination of care and yearly blood pressure monitoring), dermatologist (recognition of
cutaneous manifestations of NF-1), orthopedic surgeon (management of bone dysplasia),
ophthalmologist (evaluation for Lisch nodules and yearly vision exam), psychiatrist
(management of learning disorders, ADHD and appearance-related social issues) and
radiologist (detection and assessment of internal tumors).6, 7

Slit Lamp Opthalmologic Findings
Lisch nodules (100%)
 Small yellow-brown lesions on iris (“iris hamartomas”)
 Composed of pigmented cells, fibroblast-like cells and mast cells
 Do NOT cause any visual dysfunction or symptoms
 Not visible to the naked eye (require slit lamp evaluation)
 Not present at birth, but typically develop during childhood

DIAGNOSTIC CRITERIA
The diagnostic criteria for neurofibromatosis type 1 developed by the NIH in 1987 remain the most
widely accepted and utilized in clinical practice today. They are able to diagnose most patients within the
first year of life and essentially all patients by the age of four.2
A patient is diagnosed with NF-1 if they meet two or more of the following criteria:
1)
2)
3)
4)
5)
6)
7)

≥ 6 café au lait macules
≥ 2 neurofibromas of any type or ≥ 1 plexiform neurofibromas
≥ 2 Lisch nodules
≥ 1 first-degree relative with NF-1
Freckling in the axillary or inguinal regions
Optic glioma
Characteristic osseous lesion (e.g. sphenoid or tibial dysplasia)

Diagnostic Imaging Findings
Optic nerve glioma (15%)
 Most common CNS tumor in NF-1
 May involve the optic nerve, optic chiasm or both
 Usually asymptomatic
 May cause loss of vision, proptosis or optic disc atrophy
 Usually presents in early childhood

Diagnostic Criterion Evident on Physical Exam

Neck

Scalp and neck

ADDITIONAL COMMON FINDINGS IN NF-1
• Learning disability or ADD (50%)
• Short stature (40% are below the 10th percentile)
• Macrocephaly (35%)
• Scoliosis (20%)

PHYSICAL EXAM
• Large, hard, mobile mass extending from the posterior to the right lateral neck
• Numerous cutaneous neurofibromas

Cutaneous neurofibromas (95%)

 Similar to café au lait spots in color but smaller
 Asymptomatic and entirely benign
 Appear during early childhood

MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST)
Malignant peripheral nerve sheath tumors (MPNSTs) are the deadliest complication of NF-1. In the
majority of cases, these malignancies result from malignant sarcomatous transformation in pre-existing
plexiform neurofibromas.5 Patients typically present with the primary complaint of sudden onset of pain
or rapid increase in size of a pre-existing diffuse plexiform neurofibroma. Approximately 5% of larger
plexiform neurofibromas undergo malignant transformation and about 8% of NF-1 patients will have an
MPNST during their lifetime. This malignancy is extremely aggressive, with dismal 5-year survival rates
of around 20%. The average age of onset of MPNSTs in NF-1 patients is around 26 years.
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 Sphenoid dysplasia has classic radiographic “empty orbit sign”
 Tibial dysplasia predisposes to fracture and pseudoarthrosis
 Both are associated with low bone mineral density 4
 Scoliosis is another common finding, but is non-specific
 Almost always present from birth

SURGICAL DEBULKING AND BIOPSY
• Limited surgical debulking is carried out to reduce the mass effect of the tumor
• It is not possible to remove the entire mass
• A sample is sent off for permanent section and pathological evaluation

FOLLOW-UP FDG PET/CT
• Large MPNST with central necrosis and hypermetabolic activity (maximum SUV = 6.9)
Patient’s CT
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Sphenoid or tibial dysplasia (5%)

CT
• Right posterior-lateral bilobed neck mass, arising from C1-C2, C2-C3 neuroforamina
• Extends from the oropharynx to the hypopharynx and encroaches on the airway
• Encases the right vertebral artery and displaces the right carotid arteries anteriorly

PATHOLOGY REPORT
• Histology shows spindle and epithelial cells with marked atypia any many mitoses
• No benign neurofibroma component can be identified
• Immunohistochemical staining is negative for neurofilament and S-100 (not uncommon)
• Diagnosis is recorded as malignant peripheral nerve sheath tumor (MPNST)

Plexiform neurofibroma (25%)
 Often visible on physical exam, but may require imaging to see
 May cause disfigurement, functional impairment or threaten life
 Have a characteristic feeling similar to a “bag of worms”
 Similar histology to other types of neurofibromas
 5% undergo malignant transformation to MPNSTs

CHIEF COMPLAINT AND HISTORY OF PRESENT ILLNESS
• Right neck mass that has been enlarging over the past two months
• Progressive dysphagia to solids
• 35 pound weight loss
PAST MEDICAL HISTORY
• Neurofibromatosis type 1
• Type 2 diabetes mellitus
• Hypertension

Café au lait macules (99%)

Axillary or inguinal freckling (90%)

AN ILLUSTRATIVE CASE OF THE MANAGEMENT OF NF-1
A 72 year old female presents with a neck mass…

 Often visible on physical exam, but may require imaging to see
 May cause disfigurement, functional impairment or threaten life
 Have a characteristic feeling similar to a “bag of worms”
 Similar histology to other types of neurofibromas
 5% undergo malignant transformation to MPNSTs

Many of the diagnostic criteria for NF-1 can be identified by the primary care physician through careful
history and physical examination alone.3

 Dome shaped, soft pedunculated skin masses
 Range from skin color to bluish purple
 Axons, fibroblasts, mast, Schwann, perineural, endothelial cells
 NO risk of malignant transformation
 First appear just before puberty, increase in number with age

Routine: annual blood pressure + annual eye exam + evaluation of all 1st-degree relatives
Cutaneous neurofibromas: no intervention unless causing significant discomfort
Plexiform neurofibromas: varies widely by site and structure involved
Optic nerve gliomas: chemotherapy only if causing significant symptoms 8
Tibial dysplasia: orthopedic consult for management and prevention of fractures
Sphenoid dysplasia: usually no treatment, although cosmetic surgery may be indicated
MPNST: surgical resection with as wide of margins as possible ± radiation

Plexiform neurofibroma (25%)

HISTORY AND PHYSICAL EXAM

 Pigmented lesions darker than one’s own complexion
 Contain large granules of pigment (“macromelanosomes”)
 Asymptomatic and entirely benign
 Present from birth or childhood and fade considerably with age
 Most common reason for referral for evaluation of NF-1

Management guidelines for each of the manifestations of NF-1 vary across institutions and
individual clinicians, but some of the more generally accepted recommendations include:
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